Enjoy complimentary customisation on priority with our Enterprise License!
The immunohematology market size is forecast to increase by USD 1.07 billion, at a CAGR of 7.35% between 2023 and 2028. The market is witnessing significant growth due to several key trends. One of the major drivers is the shift by end-users towards automated immunohematology analyzers, which offer increased accuracy, efficiency, and reduced manual intervention. Another trend is the paradigm shift toward molecular immunohematology, which provides more precise and personalized diagnostic results. However, the market also faces challenges such as high maintenance costs and low reimbursement for blood components, which may hinder market growth. Despite these challenges, the market is expected to continue expanding due to the increasing demand for advanced diagnostic solutions in the healthcare industry.
Immunohematology is a critical subspecialty of clinical laboratory science that focuses on the study of blood groups, blood typing, and the interaction between antigens and antibodies in blood transfusion and blood disorders. The global market for immunohematology is driven by the increasing number of trauma cases requiring blood transfusion services, elective surgical procedures, and the rising prevalence of blood disorders such as leukemia, hemophilia, and sickle cell disease. Immunohematology tests play a crucial role in ensuring the safety and compatibility of blood products during transfusions, preventing hemolysis, transfusion-related reactions, pregnancy-related reactions, and infections like HIV. The market space for immunohematology technologies includes blood banks, healthcare services, and storage solutions for blood component services.
Awareness campaigns and advancements in immunohematology technologies are expected to boost the market's growth. The coronavirus pandemic has also highlighted the importance of blood transfusion services and the need for advanced immunohematology technologies to ensure the safety of blood products. Blood associated diseases, infections, and immunity-related reactions continue to pose challenges in the field, requiring ongoing research and innovation.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The analyzers and systems segment is estimated to witness significant growth during the forecast period. The market is expected to experience significant growth due to the increasing demand for automated analyzers in blood banks and advanced immunohematology devices in trauma centers. With the rise in hematological disorders and trauma cases, there is a wave in the requirement for blood collection, processing, testing, and storage. Immunohematology devices play a crucial role in diagnosing blood associated diseases, infections, and identifying the compatibility of blood products for transfusion. Automated immunohematology analyzers and systems are preferred by large blood banks and Tier 1 hospitals to reduce workload and save time. For instance, the National Health Service Blood and Transplantation Center (NHSBT) in the UK stores over 900 gallons of blood and performs 200-300 blood screenings every day.
Polymerase chain reaction (PCR) technology is increasingly being used for rapid and accurate diagnosis of blood-borne infections. Fully-automated devices and transfusion systems are gaining popularity due to their efficiency and diagnosis efficacy. The research fraternity and healthcare associations are focusing on developing next-generation immunohematology analyzers with better throughput and analysis time. Emergency assistance and coronavirus have further accelerated the demand for these technologies. Private and public entities are organizing blood donation camps and awareness programs to ensure a steady supply of blood products. Regulations and guidelines are being set up to ensure the spread of infection during blood storage and transportation.
Healthcare practitioners are exploring elective surgeries and non-urgent clinical interventions with emergency authorization. Convalescent plasma therapy is another emerging application of immunohematology technologies. The immune system plays a vital role in the production of plasma, which is essential for the effective treatment of various diseases.
Get a glance at the market share of various segments Request Free Sample
The analyzers and systems segment was valued at USD 1.27 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Immunohematology, a critical branch of healthcare services, focuses on diagnosing and managing hematological disorders and blood associated diseases, including infections. Immunohematology technologies, such as Polymerase chain reaction (PCR), play a pivotal role in the accurate diagnosis of these conditions. Trauma centers and hospitals rely heavily on immunohematology devices and transfusion systems for blood collection, processing, testing, and storage. Fully-automated devices ensure diagnosis efficacy and reduce analysis time, enabling emergency assistance for patients in need. Blood donation camps and awareness programs, initiated by both private entities and public entities, are essential for increasing awareness and ensuring a steady supply of blood products.
The market space for immunohematology technologies continues to expand, driven by the growing prevalence of hematological disorders and the need for advanced blood component services. The coronavirus pandemic has further highlighted the importance of immunohematology in emergency authorization of convalescent plasma therapy and the study of the immune system's response to the virus. Healthcare associations and regulations ensure the spread of infection is minimized during blood testing and storage. Healthcare practitioners rely on these technologies for elective surgeries and non-urgent clinical interventions, making immunohematology an indispensable part of modern healthcare services.
Our immunohematology market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The shift by end-users to automated immunohematology analyzers is the key driver of the market. The market is witnessing a sluggish growth due in part to consumers' hesitation towards plasma therapy and the high cost of advanced hematology devices. However, the increasing prevalence of hematological diseases such as sickle cell anemia, thalassemia, lymphoma, and leukemia, with new cases and deaths on the rise, necessitates the need for accurate diagnosis and effective treatment. To address this, manufacturers are focusing on developing automated and semi-automated immunohematology analyzers that can reduce hesitation by minimizing human errors. These advanced devices can screen large quantities of blood units in hospitals and blood banks, thereby reducing the workload on staff. Tier 1 companies like Immucor and Grifols are leading this trend with automated immunology analyzers, such as Immucor's ID-TOP and Grifols' Advia 2120, which cater to various end-users.
These devices offer software upgrades, increased storage capabilities, and compatibility with basic machines, making them an attractive investment for public and private healthcare settings. Moreover, the reagents segment, including human antiglobulin, haematology tests, genetic material like DNA and RNA, and viral load detection, is witnessing significant growth due to the need for more precise and accurate diagnosis. Clinical trials are underway to further improve the capabilities of these devices and expand their application in immunology and other fields.
The paradigm shift toward molecular immunohematology is the upcoming trend in the market. Immunohematology, a critical field in the diagnosis and treatment of hematological diseases, has experienced hesitation and sluggish growth due to the prevalence of traditional methods and infrequent use in certain consumer segments. However, the increasing incidence of diseases such as sickle cell anemia, thalassemia, lymphoma, and leukemia, with new cases and deaths on the rise according to the World Health Organization, necessitates advanced diagnostic and treatment methods. Molecular analysis in immunohematology, which helps detect the molecular and genetic basis of any antigen, is becoming increasingly adopted alongside serological and HLA typing. Blood banks and hospitals are integrating molecular immunohematology into their processes for more accurate diagnosis and cross-matching of donor and recipient blood.
The market for immunohematology is expected to grow significantly during the forecast period due to the paradigm shift towards advanced hematology devices, automation of devices, software up-gradation, increased storage capabilities, and the use of advanced reagents such as human antiglobulin, haematology tests, genetic material like DNA and RNA, and viral load detection in public and private healthcare settings. Clinical trials are also underway to further enhance the capabilities of immunohematology analyzers and manual methods.
The high cost burden is a key challenge affecting the market growth. Immunohematology, a critical segment of the healthcare industry, has experienced hesitation and sluggish growth due to the high cost burden associated with the maintenance of blood components. The handling costs, including labor, reagents, and disposables, as well as increased storage capabilities for plasma therapy and hematological diseases such as sickle cell anemia, thalassemia, lymphoma, and leukemia, which accounts for an estimated 345,000 new cases and 208,000 deaths annually, have become a significant challenge for both public and private healthcare settings. Despite the high prevalence of these diseases and the growing need for advanced hematology devices, basic machines, and manual methods continue to dominate the market.
The reagents segment, including human antiglobulin, haematology tests, and genetic material like DNA and RNA, as well as viral load detection, are essential for accurate diagnosis and treatment. However, infrequent groups and specialized tests come with higher costs and longer turnaround times, making them less adopted in clinical settings. The World Health Organization recommends the automation of devices and software up-gradation to improve efficiency and reduce errors. The cost of an RBC unit ranges from USD 150-USD 165, while the reimbursement provided is only around USD 75-USD 80. The average cost of cord blood handling is around USD 1,500 per year, leading to public and private blood banks imposing registration and annual charges on donors.
The probability of blood components such as erythrocytes and plasma being released to end-users is higher than cord blood units, but the lower reimbursements hinder their widespread adoption. Clinical trials and ongoing research aim to address these challenges and improve the affordability and accessibility of advanced immunohematology solutions.
The immunohematology market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Becton Dickinson and Co: The company offers several immunohematology products, such as BD Vacutainer serum tubes and BD Vacutainer EDTA tubes among others.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Immunohematology is a critical field in healthcare that focuses on the study of blood, its components, and related disorders. The market for immunohematology is driven by the increasing number of trauma cases requiring blood transfusion services and the rising incidence of blood disorders such as leukemia, hemophilia, sickle cell disease, and anemia. Blood banks play a crucial role in providing blood for transfusion and conducting immunohematology tests to ensure the safety of the blood supply. Elective surgical procedures and the diagnosis and treatment of blood malignancies, hemorrhagic diseases, and blood-borne infections also contribute to the growth of the market.
Immunohematology tests are essential for detecting immunity-related reactions, transplant-related reactions, and pregnancy-related reactions. The market also includes advanced technologies such as the Biovue method, DG reader net, and automatic and semi-automatic analyzers. The risk of blood-borne infections, such as HIV and hepatitis, further underscores the importance of accurate and reliable immunohematology testing.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
169 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.35% |
|
Market Growth 2024-2028 |
USD 1.07 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.71 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 36% |
|
Key countries |
US, Germany, UK, Canada, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Becton Dickinson and Co., Biomed Global, Bio Rad Laboratories Inc., biosurfit SA, Cardinal Health Inc., Calibre Scientific Inc., Danaher Corp., DIAGAST SAS, Grifols SA, Hemo bioscience Inc., HUMAN Gesellschaft fur Biochemica und Diagnostica mbH, Institut de Biotechnologies Jacques Boy, MAK SYSTEM S.A., Merck KGaA, Mesa Laboratories Inc., Quotient Ltd., Siemens AG, Thermo Fisher Scientific Inc., Tulip Diagnostics Pvt. Ltd., and Werfenlife SA |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
